관리-도구

편집 파일: 1623234693.M635625P5134.server.saraya-global.com,S=14410,W=14623:2,

Envelope-to: mehrdad.noorbakhsh@saraya.world
Delivery-date: Wed, 09 Jun 2021 18:31:33 +0800
Content-Type: text/html; charset=utf-8
From: Office WulfHoeflich <office.wulfhoeflich@futurebridge-trends.com>
To: mehrdad.noorbakhsh@saraya.world
Reply-To: office.wulfhoeflich@futurebridge-trends.com
Subject: Unique Insights on Biopharma Business Trends & Techno Commercial
 Landscapes
Message-ID: <fb45e28f-4f82-ae31-bb23-65efbc060fcd@futurebridge-trends.com>
Content-Transfer-Encoding: quoted-printable
Date: Wed, 09 Jun 2021 10:30:45 +0000 (UTC)
MIME-Version: 1.0

Dear Mehrdad=
, My name is Wulf H=C3=B6fli=
ch and I head the Business Development for FutureBridge - a Research & Advi=
sory firm providing techno-commercial insights and advisory on the future o=
f industries from a 1-to-25-year perspective. We support most Fortune 500 p=
layers like Roche, DSM, Reckitt Benckiser, ST=
ADA, Nestle, Clariant, 3M, BASF, etc. I am writing to =
you as we have a unique proposition for SARYRA </s=
trong>on the Future of Pharma/Biotech industry ecosystem and we believe tha=
t reaching out to you would be most advisable given the ambit and responsib=
ility of your profile. We are keen to share with you our experi=
ence on how market players from your value chain are addressing cha=
llenges such as selection and prioritization of Indications and di=
sease areas, digital technologies, addressing clinical and commercial unmet=
 needs, Go-No-Go decision based on scientific proof, key p=
ractices adopted by competitors in designing clinical trials, Marke=
t Access and Regulatory affairs and Health technology solutions.<b=
r /> Our insights and intelligence program is being used by Biopharma =
industry leaders to understand and act on key areas such as, Priori=
tization of Innovation opportunities in the high =
potential therapeutic areas which have substantial clinica=
l and commercial unmet needs. Our discussion will also exh=
ibit cases on changing opportunity paradigm due to change in diseas=
e patterns, impact of COVID-19 and evolvi=
ng clinical guidelines for prevention and personalization,=
 change in patient journey due to digital=
ization and awareness, scientific proof o=
f concept, regulatory bottlenecks and mar=
ket practices. Pharma-Biotech industry professionals r=
ely on our strategic and tactical insights to ideate, define business probl=
ems, reprioritize key programs and execute corporate and social strategy ac=
ross nearly fifteen therapeutic areas and rare dis=
eases wherein we bring global expertise through understanding mark=
et practices, needs and opportunities available in evolved and emerging mar=
kets. We would like to request forty five minutes of your time f=
or a digital meeting (45 minutes only) in the coming week to introduce to y=
ou our <a href=3D"http://insider.futurebridge.com/r/c66344673a3e579c47d9ee5=
e5?ct=3DYTo1OntzOjY6InNvdXJjZSI7YToyOntpOjA7czoxNDoiY2FtcGFpZ24uZXZlbnQiO2k=
6MTtpOjQwMjUyO31zOjU6ImVtYWlsIjtpOjc1MDg7czo0OiJzdGF0IjtzOjIyOiI2MGMwOTc3Zm=
NhY2EwODU5MzgwMzk4IjtzOjQ6ImxlYWQiO2k6Nzk2NDQ0NDtzOjc6ImNoYW5uZWwiO2E6MTp7c=
zo1OiJlbWFpbCI7aTo3NTA4O319&">unique hyper intelligence and insights progra=
m</a>. Would any of the following slots work for yo=
u? If yes, please write back to me with your preference. If not, please sug=
gest alternatives: <span=
 style=3D"font-family: Arial,Helvetica,sans-serif;"><ul fr-original-style=
=3D"box-sizing: border-box;" style=3D"box-sizing: border-box; margin-top: 0=
px; margin-bottom: 9px;"><li fr-original-style=3D"box-sizing: border-box;" =
style=3D"box-sizing: border-box;">Monday, 21 June &nbsp; &nb=
sp; &nbsp; &nbsp; &nbsp; &nbsp;07.00 to 07.45 CEST</li><li fr=
-original-style=3D"box-sizing: border-box;" style=3D"box-sizing: border-box=
;">Wednesday, 23 June &nbsp; &nbsp; &nbsp;08.00 to 08.45 CES=
T</li><li fr-original-style=3D"box-sizing: border-box;" style=
=3D"box-sizing: border-box;">Thursday, 24 June &nbsp; &nbs=
p; &nbsp; &nbsp; &nbsp;08.00 to 08.45 CEST</li><li fr-origina=
l-style=3D"box-sizing: border-box;" style=3D"box-sizing: border-box;"><span=
 fr-original-style=3D"font-size: 14px;" style=3D"font-size: 14px; box-sizin=
g: border-box;">Tuesday, 29 June &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 09.00 to 09.4=
5 CEST</li><li fr-original-style=3D"box-sizing: border-box;" =
style=3D"box-sizing: border-box;">Wednesday, 30 June &nbsp; =
&nbsp; &nbsp;08.00 to 08.45 CEST</li></ul>
 Best Regards, <=
/p>
 Wulf H=C3=B6flich SVP =E2=80=93 Business Development - Dipl=
.-Ing. (Univ.) 
UK 5, Chancery Lane, Londo=
n EC4A 1BL United Kingdom </s=
pan> T :+44 2034 787 710 <a h=
ref=3D"http://insider.futurebridge.com/r/0bfa49b5a511e055d0ef3e616?ct=3DYTo=
1OntzOjY6InNvdXJjZSI7YToyOntpOjA7czoxNDoiY2FtcGFpZ24uZXZlbnQiO2k6MTtpOjQwMj=
UyO31zOjU6ImVtYWlsIjtpOjc1MDg7czo0OiJzdGF0IjtzOjIyOiI2MGMwOTc3ZmNhY2EwODU5M=
zgwMzk4IjtzOjQ6ImxlYWQiO2k6Nzk2NDQ0NDtzOjc6ImNoYW5uZWwiO2E6MTp7czo1OiJlbWFp=
bCI7aTo3NTA4O319&"></a> <a href=3D"http://insider.futurebridge.com/r=
/0bfa49b5a511e055d0ef3e616?ct=3DYTo1OntzOjY6InNvdXJjZSI7YToyOntpOjA7czoxNDo=
iY2FtcGFpZ24uZXZlbnQiO2k6MTtpOjQwMjUyO31zOjU6ImVtYWlsIjtpOjc1MDg7czo0OiJzdG=
F0IjtzOjIyOiI2MGMwOTc3ZmNhY2EwODU5MzgwMzk4IjtzOjQ6ImxlYWQiO2k6Nzk2NDQ0NDtzO=
jc6ImNoYW5uZWwiO2E6MTp7czo1OiJlbWFpbCI7aTo3NTA4O319&">www.futurebridge.com</a> 
<img src=3D"https://insider.futurebridge.com/media/images/fb_logo.jpg" /=
>
 
 =
 
 
 
Please consider the environment before printing this email.</sp=
an> FutureBridge=C2=AE<=
/sup> is a registered trademark of Cheers Interactive (India) Private Limit=
ed. =E2=80=9CThis me=
ssage is intended only for the person or entity to which it is addressed an=
d contains confidential, proprietary and/or privileged information. If you =
have received this message in error, please notify the sender immediately a=
nd delete this message from your system. Reasonable precautions have been t=
aken to ensure that this message is virus-free. However, Cheers Interactive=
 (India) Private Limited does not accept any responsibility whatsoever for =
any loss or damage arising from the use of this message or any attachments =
herein=E2=80=9D. If you prefer not to =
receive any future email communication from FutureBridge for meeting reques=
t, please write to <a href=3D"mailto:meetings_unsubscribe@futurebridge.com"=
>meetings_unsubscribe@futurebridge.com</a> to unsubscribe.<img h=
eight=3D"1" width=3D"1" src=3D"http://insider.futurebridge.com/email/60c097=
7fcaca0859380398.gif" alt=3D"" />